Momentum for TELO is strongly bearish. The 14-period Slow Stochastic oscillator is below 20, the level which many analysts call oversold. This means that investors have been actively selling shares and driving the price lower. Today's volume is on track to be lighter than usual, with 75,170 shares having traded so far. The On Balance Volume indicator (OBV) shows that longer term accumulation has given way to near term selling pressure by traders as of 1:48 PM ET Wednesday, 08/20/2025
Bearish
Recent TELO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 12:15:41 PM
- Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer • ACCESS Newswire • 04/30/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 08:05:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/24/2026 01:00:13 PM
- Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn) • ACCESS Newswire • 04/24/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 01:15:16 PM
- Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer • ACCESS Newswire • 03/31/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 11:00:09 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:09 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/17/2026 09:28:20 PM
- Form DEFM14A - Definitive proxy statement relating to merger or acquisition • Edgar (US Regulatory) • 02/19/2026 10:16:10 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/19/2026 10:12:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 01:00:48 PM
- Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models • ACCESS Newswire • 02/17/2026 01:00:00 PM
- Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging • ACCESS Newswire • 02/05/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2026 12:30:43 PM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 01/23/2026 10:04:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2026 01:00:54 PM
- Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models • ACCESS Newswire • 01/05/2026 01:00:00 PM
- Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development • ACCESS Newswire • 12/18/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/17/2025 09:01:45 PM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 11/28/2025 09:59:00 PM
- Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells • ACCESS Newswire • 11/25/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2025 09:01:40 PM
- Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells • ACCESS Newswire • 11/21/2025 12:30:00 PM
